Smruthi Organics Ltd
Incorporated in 1989, Smruthi Organics Ltd
is a manufacturer of Active Pharmaceutical Ingredients[1]
- Market Cap ₹ 136 Cr.
- Current Price ₹ 118
- High / Low ₹ 182 / 105
- Stock P/E 47.4
- Book Value ₹ 59.2
- Dividend Yield 1.28 %
- ROCE 8.22 %
- ROE 5.21 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 45.5%
Cons
- The company has delivered a poor sales growth of -1.46% over past five years.
- Company has a low return on equity of 9.03% over last 3 years.
- Debtor days have increased from 97.0 to 117 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
181 | 92 | 77 | 74 | 79 | 97 | 137 | 131 | 126 | 133 | 141 | 128 | 128 | |
162 | 90 | 72 | 63 | 69 | 94 | 121 | 116 | 98 | 115 | 131 | 116 | 116 | |
Operating Profit | 19 | 2 | 5 | 11 | 10 | 3 | 17 | 15 | 29 | 18 | 10 | 12 | 12 |
OPM % | 10% | 2% | 6% | 14% | 13% | 3% | 12% | 12% | 23% | 14% | 7% | 9% | 9% |
0 | 1 | 0 | 0 | 1 | 0 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | |
Interest | 4 | 5 | 6 | 5 | 4 | 4 | 4 | 3 | 1 | 1 | 1 | 1 | 2 |
Depreciation | 5 | 6 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 6 |
Profit before tax | 10 | -9 | -6 | 2 | 3 | -5 | 10 | 12 | 24 | 14 | 4 | 5 | 4 |
Tax % | 37% | -32% | -33% | 55% | 39% | -31% | 30% | 30% | 29% | 25% | 8% | 28% | |
6 | -6 | -4 | 1 | 2 | -3 | 7 | 8 | 17 | 10 | 4 | 4 | 3 | |
EPS in Rs | 5.57 | -5.39 | -3.34 | 0.63 | 1.39 | -2.82 | 6.02 | 7.41 | 14.95 | 9.07 | 3.61 | 3.14 | 2.50 |
Dividend Payout % | 12% | 0% | 0% | 0% | 0% | 0% | 11% | 14% | 20% | 33% | 55% | 48% |
Compounded Sales Growth | |
---|---|
10 Years: | 3% |
5 Years: | -1% |
3 Years: | 0% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -12% |
3 Years: | -41% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | -21% |
1 Year: | -25% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 15% |
3 Years: | 9% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 11 | 11 | 11 | 11 | 11 |
Reserves | 37 | 31 | 26 | 27 | 28 | 25 | 33 | 39 | 49 | 56 | 57 | 58 | 56 |
47 | 43 | 45 | 37 | 33 | 31 | 28 | 16 | 10 | 3 | 6 | 12 | 17 | |
40 | 48 | 34 | 35 | 20 | 25 | 37 | 30 | 21 | 18 | 32 | 37 | 23 | |
Total Liabilities | 129 | 126 | 109 | 103 | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 108 |
45 | 41 | 35 | 32 | 30 | 30 | 30 | 32 | 31 | 33 | 37 | 40 | 40 | |
CWIP | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 6 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
83 | 83 | 72 | 69 | 54 | 54 | 69 | 56 | 60 | 53 | 66 | 77 | 61 | |
Total Assets | 129 | 126 | 109 | 103 | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 108 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 9 | 9 | 14 | 9 | 5 | 12 | 21 | 23 | 2 | 12 | 4 | |
-13 | -2 | -1 | 0 | -0 | -3 | -4 | -5 | -3 | 7 | -10 | -7 | |
6 | -6 | -8 | -14 | -9 | -2 | -5 | -17 | -7 | -12 | -2 | 3 | |
Net Cash Flow | -1 | 2 | -1 | -0 | 0 | 0 | 2 | -1 | 13 | -3 | 0 | -0 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 64 | 102 | 103 | 95 | 97 | 95 | 97 | 68 | 62 | 78 | 96 | 117 |
Inventory Days | 113 | 133 | 123 | 166 | 145 | 126 | 92 | 75 | 100 | 91 | 96 | 150 |
Days Payable | 82 | 132 | 106 | 128 | 123 | 130 | 120 | 97 | 81 | 50 | 98 | 144 |
Cash Conversion Cycle | 94 | 104 | 120 | 133 | 119 | 92 | 68 | 46 | 80 | 118 | 93 | 123 |
Working Capital Days | 88 | 109 | 113 | 100 | 88 | 93 | 78 | 70 | 76 | 107 | 86 | 111 |
ROCE % | 18% | -5% | 0% | 9% | 10% | -1% | 21% | 25% | 39% | 21% | 7% | 8% |
Documents
Announcements
- Closure of Trading Window 29 Mar
- Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Feb
-
Announcement under Regulation 30 (LODR)-Change in Management
4 Feb - Re-appointment of Managing and Joint Managing Directors.
-
Announcement under Regulation 30 (LODR)-Change in Management
4 Feb - Outcome of Board meeting including financial results and director re-appointments.
-
Integrated Filing (Financial)
4 Feb - Board meeting outcome including financial results and director reappointments.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
SOL is in the pharmaceutical business with presence in manufacturing bulk drugs and active pharmaceutical ingredients